On ECHEMI
Home > Drugs > Suzhou Erye Pharmaceutical Co., Ltd.
Suzhou Erye Pharmaceutical Co., Ltd.
  • Founded in:

    1981-04-13
  • Country:

    China China
  • Address:

    No. 2, Dongqiao Anmin Road, Huangdai Town, Xiangcheng District, Suzhou City
  • Tax NO.:

    913205001377026284
  • Registered Funds:

    300 million yuan
  • Website:

  • Email:

Related Drugs
Pefloxacin Mesylate for Injection
The main ingredient of this product is pefloxacin mesylate.
Name Description Content CAS NO. Registered Holders
Pefloxacin mesylate

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.

More

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.

70458-95-6 4
Pefloxacin Mesylate for Injection
The main ingredient of this product is pefloxacin mesylate.
Name Description Content CAS NO. Registered Holders
Pefloxacin mesylate

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.

More

Quinolone antibacterial drugs inhibit bacterial DNA helicase and have a broad-spectrum antibacterial effect. They have strong antibacterial activity against Enterobacter bacteria such as Escherichia coli, Klebsiella, Proteus, Shigella, Salmonella typhi, etc., as well as influenza bacillus and Neisseria. They also have certain antibacterial effects on Staphylococcus aureus and Pseudomonas aeruginosa. They have only mild effects on pneumococci, various groups of streptococci and enterococci.

70458-95-6 4
Bumetanide for injection
Main ingredient: Bumetanide. Chemical name: 5-n-butylamino-4-phenoxy-3-aminosulfonylbenzyl.
Name Description Content CAS NO. Registered Holders
Bumetanide

The effect on water and electrolyte excretion is basically the same as furosemide, and its diuretic effect is 20 to 60 times that of furosemide. It mainly inhibits the active reabsorption of NaCl by the thick wall segment of the ascending limb of the renal tubular loop of Henle, and also inhibits the reabsorption of Na+ in the proximal tubule, but has no effect on the distal tubule, so the potassium excretion effect is less than furosemide. It can inhibit the activity of prostaglandin degrading enzymes, increase the content of prostaglandin E2, and thus have a vasodilatory effect. Dilation of renal blood vessels, reduction of renal vascular resistance, and increase of renal blood flow, especially deep renal cortical blood flow, are of great significance in the diuretic effect of bumetanide, and are also the theoretical basis for its use in the prevention of acute renal failure. In addition, unlike other diuretics, loop diuretics increase the flow of renal tubular fluid while the glomerular filtration rate does not decrease, which may be related to the reduction of chloride flowing through the macula densa, thereby weakening or blocking the glomerular-tubular balance. Bumetanide can dilate the pulmonary capacitance veins and reduce the permeability of pulmonary capillaries. Its diuretic effect can reduce the amount of blood returning to the heart and the left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure. Since bumetanide can reduce the permeability of pulmonary capillaries, it provides a theoretical basis for its treatment of adult respiratory distress syndrome.

More

The effect on water and electrolyte excretion is basically the same as furosemide, and its diuretic effect is 20 to 60 times that of furosemide. It mainly inhibits the active reabsorption of NaCl by the thick wall segment of the ascending limb of the renal tubular loop of Henle, and also inhibits the reabsorption of Na+ in the proximal tubule, but has no effect on the distal tubule, so the potassium excretion effect is less than furosemide. It can inhibit the activity of prostaglandin degrading enzymes, increase the content of prostaglandin E2, and thus have a vasodilatory effect. Dilation of renal blood vessels, reduction of renal vascular resistance, and increase of renal blood flow, especially deep renal cortical blood flow, are of great significance in the diuretic effect of bumetanide, and are also the theoretical basis for its use in the prevention of acute renal failure. In addition, unlike other diuretics, loop diuretics increase the flow of renal tubular fluid while the glomerular filtration rate does not decrease, which may be related to the reduction of chloride flowing through the macula densa, thereby weakening or blocking the glomerular-tubular balance. Bumetanide can dilate the pulmonary capacitance veins and reduce the permeability of pulmonary capillaries. Its diuretic effect can reduce the amount of blood returning to the heart and the left ventricular end-diastolic pressure, which is helpful for the treatment of acute left heart failure. Since bumetanide can reduce the permeability of pulmonary capillaries, it provides a theoretical basis for its treatment of adult respiratory distress syndrome.

28395-03-1 40
Oxymatrine for injection
The main ingredient of this product is matrine, and its chemical name is: oxymatrine.
Name Description Content CAS NO. Registered Holders
Ammothamnine

It can reduce the level of DHBV-DNA in the serum of ducks infected with hepatitis B virus (DHBV) and has a protective effect on toxic liver damage in mice caused by CCL4 and galactosamine

More

It can reduce the level of DHBV-DNA in the serum of ducks infected with hepatitis B virus (DHBV) and has a protective effect on toxic liver damage in mice caused by CCL4 and galactosamine

16837-52-8 11
Enoxaparin Sodium
Name Description Content CAS NO. Registered Holders
Heparin sodium

9041-08-1 83
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.